Stock Events

Stock Events

MindMaze Therapeutics SA 

$0.177900
83
+$0.01+6.09%Thursday 14:41

Statistics

Day High
0.1779
Day Low
0.1779
52W High
4.05
52W Low
0.16769
Volume
2,500
Avg. Volume
44
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 27Expected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2026
-0
-0
0
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLFTY. It's not an investment recommendation.
Apple
10
AAPL
Tesla
9
TSLA
Microsoft
8
MSFT
AMD
6
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that competes in developing treatments for viral diseases, a similar area of focus as Relief Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in developing medications for serious medical conditions, directly competing with Relief Therapeutics in the biopharmaceutical space.
Moderna
MRNA
Mkt Cap88.52B
Moderna is known for its mRNA technology used in vaccines and therapies, competing with Relief Therapeutics in the innovative treatment sector.
Pfizer
PFE
Mkt Cap173.95B
Pfizer develops and manufactures drugs and vaccines, including treatments for COVID-19, making it a competitor in the pandemic response market.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is a global biopharmaceutical company working on vaccines and treatments for various diseases, including COVID-19, competing with Relief Therapeutics.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech SE, in partnership with Pfizer, developed a COVID-19 vaccine, directly competing with Relief Therapeutics' efforts in pandemic-related treatments.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division, develops treatments and vaccines, including for COVID-19, competing in the same space as Relief Therapeutics.
Novavax
NVAX
Mkt Cap1.66B
Novavax is focused on developing vaccines, including for COVID-19, making it a direct competitor in the vaccine development space.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics works on therapies for COVID-19, cancer, and pain, competing with Relief Therapeutics in multiple therapeutic areas.

About

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.
Show More
CEO
Zach W. Henderson
Employees
31
Country
Switzerland
ISIN
US60269B1052

Listings

F
DE
V6M.F
MU
DE
V6M0.MU
LSE
GB
0QKQ.LSE
OTC Link
US
MMTZF

0 Comments

Share your thoughts

FAQs

What is MindMaze Therapeutics SA stock price today?▼
The current price of RLFTY is $0.18 USD — it has increased by +6.09% in the past 24 hours. Watch MindMaze Therapeutics SA stock price performance more closely on the chart.
What is MindMaze Therapeutics SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange MindMaze Therapeutics SA stocks are traded under the ticker RLFTY.
When is the next MindMaze Therapeutics SA earnings date?▼
MindMaze Therapeutics SA is going to release the next earnings report on April 15, 2027.
How many employees does MindMaze Therapeutics SA have?▼
As of November 7, 2026, the company has 31 employees.
In which sector is MindMaze Therapeutics SA located?▼
MindMaze Therapeutics SA operates in the Health & Wellness sector.
When did MindMaze Therapeutics SA complete a stock split?▼
The last stock split for MindMaze Therapeutics SA was on May 5, 2023 with a ratio of 1:2.
Where is MindMaze Therapeutics SA headquartered?▼
MindMaze Therapeutics SA is headquartered in Geneva, Switzerland.